The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …

The novel coronavirus disease 2019 (COVID-19) pandemic has spread worldwide, and
finding a safe therapeutic strategy and effective vaccine is critical to overcoming severe …

Cost-effective, efficacious therapeutics are urgently needed to combat the COVID-19
pandemic. In this study, we used camelid immunization and proteomics to identify a large …

Containment of the COVID-19 pandemic requires reducing viral transmission. Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is initiated by membrane fusion …

Abstract SARS-CoV-2, the causative agent of COVID-19, features a receptor-binding domain
(RBD) for binding to the host cell ACE2 protein,,,,–. Neutralizing antibodies that block RBD …

There are currently few approved effective treatments for SARS-CoV-2, the virus responsible
for the COVID-19 pandemic. Nanobodies are 12–15 kDa single-domain antibody fragments …

The route of administration of a therapeutic agent has a substantial impact on its success.
Therapeutic antibodies are usually administered systemically, either directly by intravenous …

To address the COVID-19 pandemic, there has been an unprecedented global effort to
advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical …

The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are initiated by
attachment of the receptor-binding domain (RBD) on the viral Spike protein to angiotensin …